Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
Date:5/16/2011

tin will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its third quarter of fiscal year 2011 financial results and plans for its programs under development.  Individuals interested in listening to the conference call live can dial 1-866-316-1363 (domestic) or 1-913-312-0861 (international), Pass code 2950108. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), Pass code 2950108.  The webcast and telephone replay will be available through May 23, 2011.  

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Ex
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/26/2014)...  NeuroSigma, Inc., a Los Angeles ... today announced that it has filed a registration statement ... Commission relating to a proposed initial public offering of ... offered and the price range for the proposed offering ... will act as the book-running manager for the proposed ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... sizes and shapes, scientists now understand how they lose ... weighing any single atom. Such ultrasensitive measurements could ... and diagnostics, enabling the detection of minuscule disease-causing agents ... level. Researchers are interested in nanosized materials because ...
... ... , ... CA (Vocus) - GreenHouse announced today that on July 30, 2009 it will introduce ... a high performance ethanol fuel for cars. The first installation of the E-Fuel ...
... , , , ... Calif. and LONDON, July 27 Amgen (Nasdaq: AMGN ... companies will share commercialization of Amgen,s monoclonal antibody denosumab for postmenopausal ... product is approved in these countries. Amgen will commercialize the ...
Cached Biology Technology:1 nano-step closer to weighing a single atom 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
(Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and ... Annual International Conference (EMBC,14), this year being held at ... Chicago, Illinois , from Tuesday, August 26 through ... and industry professionals in science, medicine, and engineering are ... This year,s conference theme is ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... young scientists have received postdoctoral fellowships from the National ... they conduct research with the eventual aim of protecting ... mentorship from a faculty member at their home institution, ... research teams. This allows them to interact with some ...
... from a pivotal, large-scale Phase III trial, published online ... , show that the RTS,S malaria vaccine candidate can ... immunization with a control vaccine, infants (aged 6-12 weeks ... episodes of both clinical and severe malaria and had ...
... Nearly 3,000 insect scientists are expected to attend Entomology 2012, ... this November in Knoxville, TN. Members of the media who ... press pass. WHEN: November 11-14, 2012 ... WHAT: Entomology 2012 is the 60th Annual ...
Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 3RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 4
... Edited by N.C. Price (1996) ... information on protein chemistry and ... of proteins. Data on the ... crystalization, size determination, amino acid ...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Biology Products: